天津医药
天津醫藥
천진의약
TIANJIN MEDICAL JOURNAL
2013年
7期
636-639
,共4页
王勇%杨世诚%李英%周小雨%李珊珊%刘园园%陈永利%刘晓罡%付乃宽
王勇%楊世誠%李英%週小雨%李珊珊%劉園園%陳永利%劉曉罡%付迺寬
왕용%양세성%리영%주소우%리산산%류완완%진영리%류효강%부내관
乙酰半胱氨酸%肾疾病%造影剂%碘帕醇%血管成形术,经腔,经皮冠状动脉%对比剂肾病
乙酰半胱氨痠%腎疾病%造影劑%碘帕醇%血管成形術,經腔,經皮冠狀動脈%對比劑腎病
을선반광안산%신질병%조영제%전파순%혈관성형술,경강,경피관상동맥%대비제신병
acetylcysteine%kidney diseases%contrast media%iopamidol%angioplasty,transluminal,percutaneous coro-nary%contrast induced nephropathy
目的探讨N-乙酰半胱氨酸(NAC)对择期经皮冠状动脉介入治疗(PCI)术后发生对比剂肾病(CIN)是否具有预防作用。方法选取行择期PCI术的患者521例,随机分为NAC组和常规治疗组,其中NAC组260例,给予NAC+水化治疗;常规治疗组261例,仅给予水化治疗。观察2组PCI术前及术后72 h血肌酐(Scr)、尿素氮(BUN)、肌酐清除率(Ccr)、C-反应蛋白(CRP)、β2微球蛋白(β2-MG)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、过氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GPX)及CIN发病率的变化。结果(1)NAC组的CIN发病率(6.2%)与常规治疗组(3.8%)差异无统计学意义(χ2=1.48,P>0.05)。(2)2组PCI术前的血Scr、BUN、Ccr、CRP、β2-MG、TNF-α、IL-6、SOD及GPX水平差异无统计学意义(P>0.05)。(3)PCI术后72 h,2组CRP、SOD、GPX均较术前升高(P<0.05);NAC组CRP、SOD、GPX水平低于常规治疗组(P<0.05);NAC组Scr、BUN、β2-MG、Ccr水平较常规治疗组无明显变化(P>0.05)。结论 NAC对PCI术后CIN的发生可能无预防作用。
目的探討N-乙酰半胱氨痠(NAC)對擇期經皮冠狀動脈介入治療(PCI)術後髮生對比劑腎病(CIN)是否具有預防作用。方法選取行擇期PCI術的患者521例,隨機分為NAC組和常規治療組,其中NAC組260例,給予NAC+水化治療;常規治療組261例,僅給予水化治療。觀察2組PCI術前及術後72 h血肌酐(Scr)、尿素氮(BUN)、肌酐清除率(Ccr)、C-反應蛋白(CRP)、β2微毬蛋白(β2-MG)、腫瘤壞死因子-α(TNF-α)、白細胞介素-6(IL-6)、過氧化物歧化酶(SOD)、穀胱甘肽過氧化物酶(GPX)及CIN髮病率的變化。結果(1)NAC組的CIN髮病率(6.2%)與常規治療組(3.8%)差異無統計學意義(χ2=1.48,P>0.05)。(2)2組PCI術前的血Scr、BUN、Ccr、CRP、β2-MG、TNF-α、IL-6、SOD及GPX水平差異無統計學意義(P>0.05)。(3)PCI術後72 h,2組CRP、SOD、GPX均較術前升高(P<0.05);NAC組CRP、SOD、GPX水平低于常規治療組(P<0.05);NAC組Scr、BUN、β2-MG、Ccr水平較常規治療組無明顯變化(P>0.05)。結論 NAC對PCI術後CIN的髮生可能無預防作用。
목적탐토N-을선반광안산(NAC)대택기경피관상동맥개입치료(PCI)술후발생대비제신병(CIN)시부구유예방작용。방법선취행택기PCI술적환자521례,수궤분위NAC조화상규치료조,기중NAC조260례,급여NAC+수화치료;상규치료조261례,부급여수화치료。관찰2조PCI술전급술후72 h혈기항(Scr)、뇨소담(BUN)、기항청제솔(Ccr)、C-반응단백(CRP)、β2미구단백(β2-MG)、종류배사인자-α(TNF-α)、백세포개소-6(IL-6)、과양화물기화매(SOD)、곡광감태과양화물매(GPX)급CIN발병솔적변화。결과(1)NAC조적CIN발병솔(6.2%)여상규치료조(3.8%)차이무통계학의의(χ2=1.48,P>0.05)。(2)2조PCI술전적혈Scr、BUN、Ccr、CRP、β2-MG、TNF-α、IL-6、SOD급GPX수평차이무통계학의의(P>0.05)。(3)PCI술후72 h,2조CRP、SOD、GPX균교술전승고(P<0.05);NAC조CRP、SOD、GPX수평저우상규치료조(P<0.05);NAC조Scr、BUN、β2-MG、Ccr수평교상규치료조무명현변화(P>0.05)。결론 NAC대PCI술후CIN적발생가능무예방작용。
Objective To investigate the preventive effect of N-acetylcysteine (NAC) on contrast-induced nephropa-thy (CIN) in patients undergoing elective percutaneous coronary intervention (PCI). Methods A total of 521 patients under-went PCI in Tianjin were randomly divided into conventional treatment group (n=261) and NAC treatment group (n=260). NAC treatment group was given oral NAC (600 mg twice daily) for 48 h and 72 h before PCI plug hydration therapy, and the conventional treatment group was given only hydration therapy. The serum levels of creatinine(Scr), urea nitrogen(BUN), creatinine clearance rate (Ccr), C-reactive protein (CRP),β2-microglobulin(β2-MG), tumor necrosis factor-α(TNF-α), inter-leukin-6 (IL-6), superoxide dismutase (SOD), glutathione peroxidase (GPX) and incidence of CIN were detected at admission and 72 h after the procedure. Results (1) There was no significant difference in the incidence of CIN between NAC treat-ment group (6.2%) and conventional treatment group (3.8%,χ2=1.48, P>0.05). (2) There were no significant differences in se-rum levels of Scr, BUN, Ccr, CRP,β2-MG, TNF-α, IL-6, SOD and GPX before PCI ( P>0.05). (3) The serum levels of CRP, SOD and GPX were significantly higher 72 h after the procedure in two groups ( P<0.05). There were significantly lower se-rum levels in CRP, SOD and GPX in NAC treatment group than those of conventional treatment group ( P<0.05). There were no significant differences in serum levels of Scr, BUN,β2-MG and Ccr between NAC treatment group and conventional treat-ment group ( P >0.05). Conclusion N-acetylcysteine may have no beneficial effect on the prevention of CIN after PCI.